NCT02182323View on ClinicalTrials.gov

Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2006

Conditions
Healthy
Interventions
DRUG

BI 201335 NA

DRUG

Placebo solution

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY